COMP <GO>
ECG vs PG // EV/EBITDA & P/E VALUATION
Everus Construction Group Inc. (NYSE) VS. Procter & Gamble Company (The) (NYSE) • 15-METRIC TALLY: ECG 5
— PG 10
▲ EV/EBITDA & P/E VALUATION LEADER: ECG
LAST: $102.63 (-5.02%) • MKT CAP: $5.52B
valuation
13.7x
LAST: $161.57 (+0.61%) • MKT CAP: $372.21B
valuation
16.2x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ECG VS. PG)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ECG | PG | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 12.10% | 51.20% | -39.10 | PG | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 30.40% | 25.40% | +5.00 | ECG | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 13.7x | 16.2x | -2.50 | ECG | /valuation <GO> |
| Free Cash Flow Yield | -0.21% | 3.77% | -3.98 | PG | /fcf-yield <GO> |
| Operating Margin | 7.10% | 24.30% | -17.20 | PG | /operating-margins <GO> |
| Net Profit Margin | 5.40% | 19.00% | -13.60 | PG | /net-margins <GO> |
| Revenue Growth (YoY) | 31.50% | 0.30% | +31.20 | ECG | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.65% | -2.65 | PG | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 6.47 | 5.59 | +0.88 | ECG | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | PG | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.30% | 6.50% | +0.80 | PG | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 40.3 | 62.7 | -22.37 | PG | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.13 | 0.87 | +0.26 | ECG | /macro-sensitivity <GO> |
| Forward P/E Multiple | 22.9x | 21.7x | +1.20 | PG | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $5.52B | $372.21B | -$366.69B | PG | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ECG REV | PG REV | ECG GROSS % | PG GROSS % | ECG FCF | PG FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.75B | $84.28B | 12.1% | 51.2% | -$11.7M | $14.04B |
| FY 2024 | $2.85B | $84.04B | 11.9% | 51.4% | $35.1M | $16.52B |
| FY 2023 | $2.85B | $82.01B | 44.0% | 44.0% | $42.9M | $13.16B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ECG // BETA 1.13
PG // BETA 0.87